Rothenberg Mace
Known title: DirectorCIK: 0001873988
Rothenberg Mace's purchase track record
Rothenberg Mace has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/14/2024 | TNGX | $74K | -36.0% | -61.2% | -0.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TNGX | ▲ Buy | Grant | 4,000 | $0 | 6/5/2026 | View on chart |
| TNGX | ▲ Buy | Grant | 6,250 | $0 | 6/5/2025 | View on chart |
| TNGX | ▲ Buy | Open Market | 10,000 | $38K | 11/18/2024 | View on chart |
| TNGX | ▲ Buy | Open Market | 10,000 | $36K | 11/14/2024 | View on chart |
| TNGX | ▲ Buy | Grant | 6,250 | $0 | 6/5/2024 | View on chart |
| TNGX | ▲ Buy | Grant | 5,000 | $0 | 6/6/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026
Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026. Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.